SecBot SecBot
EFFECT ·Filed Apr 15, 2026

LYEL

Lyell Immunopharma, Inc.
NEUTRAL
Impact 2/10
Horizondays Processed7mo ago SEC9999999995-26-001185
IPO/offering going effective
Actionable Insight • Neutral

Traders should monitor for potential secondary sales by institutional holders, which could increase near-term share supply and pressure stock price; however, no immediate dilution or capital raise by the company is occurring.

DirectionNeutral
Confidencehigh
Horizondays

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$23.84
T+0 close · Apr 15, 2026 · via day close
Latest settled
−37.04%
T+60 · $15.01
Vs SPY
−45.18%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 15 $23.84entry
  2. T+1 · 7mo ago −0.59%α −0.84% · $23.70
  3. T+5 · 7mo ago +3.94%α +2.30% · $24.78
  4. T+20 · 6mo ago −19.25%α −25.30% · $19.25
  5. T+60 · 4mo ago −37.04%α −45.18% · $15.01
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Lyell Immunopharma's S-3 shelf registration has become effective, allowing the resale of up to 1,952,360 shares by selling stockholders. The company will not receive proceeds from any sales under this registration.

Key Facts

  • S-3 shelf registration effective as of April 14, 2026
  • Enables resale of 1,952,360 shares of common stock by selling stockholders
  • Shares were acquired in a private placement on March 6, 2026, at $25.61 per share
  • Company will not receive any proceeds from resales under this registration
  • Selling stockholders include institutional investors such as ARCH Venture Fund, Gates Frontier, and Explore Investments

Financial Impact

No direct financial impact to Lyell Immunopharma, no proceeds from resales

dilutionshareholder structure

Risk Factors

  • Potential for increased share volatility if selling stockholders offload large positions
  • Perception of negative sentiment if early investors begin exiting positions

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
EFFECT Filing (Primary)9999999995-26-001185
Document: 9999999995-26-001185-index.html9999999995-26-001185
Document: 9999999995-26-001185.txt9999999995-26-001185

Track record

21 reports on LYEL

Performance horizon

5 of 5 bullish or bearish reports moved the stock their way by T+1. Best: +17.99% at T+60 after the Jun 8, 2026 report. 5 of 5 went positive at some point.

Filters
  1. Nov 13, 20263d ago S-3 Neutral 3/10 Entry $14.30 Now $14.65 +2.45% settles Nov 17
  2. Nov 12, 20264d ago Insider Cluster Bullish 6/10 Entry $14.30 to $14.65 Now $14.65 +2.45% ▲ +2.45% +4.36% vs SPY
  3. Nov 10, 20266d ago SC 13G/A Neutral 2/10 Entry $16.86 to $15.64 Now $14.65 −13.11% ▼ −7.24% −6.88% vs SPY
  4. Nov 5, 202611d ago Insider Cluster Bullish 7/10 Entry $14.86 to $15.42 Now $14.65 −1.41% ▲ +3.77% +1.40% vs SPY
  5. Nov 4, 202612d ago 8-K Neutral 4/10 No price data
  6. Nov 4, 202612d ago Press Release Neutral 4/10 Entry $15.00 to $14.86 Now $14.65 −2.33% ▼ −0.93% −1.25% vs SPY
  7. Nov 4, 202612d ago 8-K Bearish 5/10 Entry $15.43 to $15.00 Now $14.65 +5.06% ▲ +2.79% −1.62% vs SPY
  8. Nov 4, 202612d ago Press Release Neutral 4/10 Entry $15.43 to $15.00 Now $14.65 −5.06% ▼ −2.79% +1.62% vs SPY
  9. Aug 25, 202611w ago Insider Cluster Neutral 4/10 Entry $14.80 to $14.61 Now $14.65 −1.01% ▼ −1.28% −1.94% vs SPY
  10. Jul 22, 202616w ago EFFECT Neutral 4/10 Entry $12.84 to $12.78 Now $14.65 +14.10% ▼ −0.47% +0.77% vs SPY
Showing 10 of 21

US Market Status

Market Closed · Opens in 6h 39m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 15, 2026